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Introduction
Tuberculosis is a major public health problem in
Pakistan with an estimated prevalence of 355/100000 and a
mortality rate of 33/100000.1 Multi-drug resistant
tuberculosis (MDR-TB), defined as mycobacterium
tuberculosis (MTB) resistant to both isoniazid and rifampicin,
is a worldwide problem with an estimated 14 million cases in
2009.1 The rate of MDR-TB in Pakistan is reported to be
between 1.8% of the new TB cases.2
Rapid molecular methods for the diagnosis of
isoniazid and rifampicin resistance in MTB are based on the
detection of genetic mutations. Mutation in the rpoB gene
encoding β-subunit of RNA polymerase is estimated to be
responsible for 95% of rifampicin resistance.3 Mutations in
katG, inhA, kasA, oxyR and ahpC result in isoniazid
resistance with 60-90% of mutations attributed to codon 315
of katG, and in the promoter region of inhA.4
Commercial assays for rapid detection of isoniazid
and rifampicin resistance rely on a selected number of
common reported mutations. The World Health Organisation
recommended the use of line-probe assays (LiPA) for smear-
positive pulmonary specimens in a 2008 policy statement.5 It
also emphasised the need for their evaluation in different
epidemiological settings. GenoType® MTBDRplus is one
such commercially available assay which has been previously
evaluated in Europe, South Africa, Far East and North
America.6-10 While sensitivity of rifampicin resistance
detection by this method has been reported to be as high as
94-100%, that for isoniazid has remained low with a reported
range of 57-95%.4 Majority of this data has been reported
from regions mentioned above and some from China,
Thailand and Vietnam.8-10 There is, however, no information
on its performance in South Asia (Pakistan, Iran, India and
Bangladesh). Thus, there is a need for evaluation of this
important tool in these TB endemic regions.
In a study of 62 MDR isolates from Pakistan Ali et al.
reported that 90% of RIF-resistant mutations were in the
mutational hot spot region of rpoB gene, while 77% of INH-
resistant mutations were in the hot spot regions of katG gene
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Abstract
Objective: To assess the efficacy of a line-probe assay ∆ (LiPA) as rapid diagnostic test for early detection of
drug-resistant tuberculosis compared to conventional susceptibility methods in Pakistan.
Methods: Resistance to rifampicin (RIF) and isoniazid (INH) in 108 smear-positive pulmonary tuberculosis
samples was detected using a line-probe assay [GenoType® MTBDRplus (Hain Lifescience, GmbH, Nehren,
Germany)] at the clinical microbiology laboratory of Aga Khan University Hospital in May, 2009. Results were
compared with susceptibilities performed while using agar proportion. 
Results: In comparison to the agar proportion method, the detection rate and specificity of resistance using
MTBDR plus was 92.5% and 98.2% for rifampicin, and 76.3% and 100% for isoniazid. 
Mutations in codons 531 and 533 of rpoB gene (62%S531L) were responsible for 67.9% of rifampicin resistance.
S315T mutation of katG gene was detected in 55.9% and inhA promoter mutation at positions -15 (C15T) in
11.9% of isoniazid resistant isolates. Four phenotypically rifampicin-resistant and 14 isoniazid-resistant strains
were not detected by MTBDRplus. Sequencing these strains revealed mutations in 4 strains; 2 in rpoB gene
S531W, del518 and 2 in katG genesW300L, S315N. Hence, two phenotypic rifampicin-resistant and 13
phenotypic isoniazid-resistant strains were not detected by the commercial line probe assay. 
Conclusion: The study showed that MTBDRplus had a high detection rate for rifampicin resistance. However,
additional probes need to be included in the assay to improve the detection of isoniazid-resistant mycobacterium
tuberculosis strains in Pakistan. 
Keywords: Rifampicin, Isoniazid, Tuberculosis, MTBDRplus, Pakistan. (JPMA 62: 767; 2012)
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with 1.6% in inhA promoter region.3 Indian reports of MDR
strains in Delhi showed that rpoB and katG mutations were
variable, with S531L rpoB and S315T katG being
predominant.11
Apart from rapid detection of MDR isolates, LiPAs
play a significant role in the detection of hetero-resistance;
whereby both wild type and mutant genes are detected within
the same specimen. Hetero-resistance is a preliminary stage
towards full resistance.12 Its detection using conventional
drug susceptibility method is labour-intensive. Hence, LiPA
is definitely advantageous due to its rapid detection
capacity.12,13
In the present study, sensitivity and specificity of
LiPA (GenoType® MTBDRplus) in detecting RIF and INH
resistant MTB strains from smear-positive pulmonary
samples from Pakistan were compared with the conventional
susceptibility method. Frequencies of mutations in rpoB,
katG and inhA genes in MTB detected within the study
isolates were analyzed and isolates showing hetero-resistance
were identified. 
Materials and Methods
The Clinical laboratories of Aga Khan University
Hospital (AKUH) receive specimens from all major cities of
Pakistan; and the average volume of samples for TB smear
and cultures is around 200/week. The present cross-sectional
study was conducted after due approval was obtained from
the Ethics Review Committee at the Clinical Microbiology
Laboratory of AKUH in May 2009, involving 111 pulmonary
samples (sputa, tracheal aspirates and bronchoalveolar lavage
fluid) submitted for Acid Fast Bacilli (AFB) smear and
culture. The samples were randomly selected based on AFB
smear positivity. Smear-positive decontaminated pulmonary
samples were simultaneously tested for LiPA and cultured for
phenotypic drug susceptibility. Phenotypic results were used
as the gold standard. Of the total 111 samples, 108 results
were included in the final analysis. Three specimens were
excluded; one yielding a growth of non-TB mycobacteria,
and two due to un-interpretable results.
The pulmonary samples were decontaminated with
1% NALC/NaOH and centrifuged. Auramine-rhodamine
fluorescent AFB smear was read and the specimen inoculated
onto Lowenstein-Jensen (LJ) slant and MGIT (Becton
Dickinson Diagnostic Instruments Systems, Sparks, MD,
USA) supplemented with oleic acid-albumin-dextrose-
catalase (OADC) and PANTA (polymyxin B, amphotericin
B, nalidixic acid, trimethoprim and azlocillin). Positive-
signalling MGITs were removed daily and sub-cultured on
7H10 agar while LJ slants were observed weekly for
mycobacterial growth. Mycobacterium tuberculosis was
identified by susceptibility to PNB 0.5 mg/ml. Cultures
positive for mycobacteria were tested for susceptibility to
rifampicin (1.0 µg/ml) and isoniazid (0.2 and 1.0 µg/ml) by
agar proportion method. Susceptibility results were read at 2
and 3 weeks. All isolates were saved at -80?C. 
LiPA was performed using GenoType® MTBDRplus
according to the manufacturer's instructions. Briefly, 0.5 ml
of decontaminated AFB smear-positive sputum, TA or BAL
specimen was centrifuged, heat inactivated, sonicated and re-
centrifuged. Supernatant (100µl) was saved as the extracted
DNA. Quality and quantity of DNA was assessed on
NanoDrop™ 1000 Spectrophotometer (Thermo Fischer
Scientific) before running multiplex-PCR on 5µl of DNA
using primers and de-oxyribonucleotide precursors provided
by Hain Lifescience (Nehren, Germany), as part of the kit.
Amplicons were then hybridised to the DNA probe-labelled
strip provided in Genotype® MTBDRplus assay. The assay
included conjugate, amplification and gene locus control for
M. tuberculosis-complex, rpoB, katG and inhA. 
While interpretating the data, an isolate was
considered sensitive if all wild type probes tested positive and
there was no hybridisation with mutation detection probes.
The absence of at least one wild type probe indicated
resistance of the tested strain to the respective antibiotic.
Hetero-resistance was defined when bands for both wild type
and mutation probes were detected simultaneously in a
specimen.12
Gene sequencing for katG and rpoB was also done.
For the purpose, isolates giving discordant results between
phenotypic susceptibility and LiPA were revived on 7H10
agar for re-testing by phenotypic method and nucleic acid
sequencing. A loopful of bacteria was suspended in 300- µl of
molecular grade water, heat inactivated, sonicated and
centrifuged. Supernatant was used as DNA template and
amplification was performed by using specific cycles14 on a




GTCAGTGGCCAGCATCGTCGGGGA) were for 81 base-
pair hyper-variable region of rpoB, and codon 315 of katG
gene. Amplicons were purified using the QIA quick Qiagen
PCR purification kit. The purified amplicons were shipped to
Macrogen Incorporated, South Korea for DNA sequencing.
Sequencing results were analysed upon comparison with
MTB wild type strains by BLAST software from the NCBI
web link (www.ncbi.nlm.nih.gov/BLAST). Amplicons of the
three strains showing rare mutations; W300L of katG, 518
deletion and H526N of rpoB - were re-sequenced to confirm
the presence of mutations.
Descriptive analysis was performed using SPSS
version 17.0. 
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Results
A total of 111 AFB smear-positive decontaminated
pulmonary samples were tested with GenoType®
MTBDRplus. Three specimens were excluded; one yielding
a growth of non-tuberculous mycobacteria, and two due to
un-interpretable results. This left 108 results for the final
analysis (107 sputa, 1 BAL). Of these, 56 were from females
(female/male ratio was 1.08). Age ranged from 10 to 86 years
(Mean 33.67 ±15.59 years). 
While phenotypic proportion method identified
49.1% and 54.6% of the 108 strains as resistant to RIF and
INH respectively (Table-1), using the LiPA, the
corresponding resistance rates were 47.2% and 41.7%.
MTBDRplus failed to detect 3.7% (n=3) of RIF and 23.7%
(n=14) INH-resistant strains.
Five strains identified as sensitive to both RIF and
INH by MTBDRplus assay failed to grow on culture and
could not be verified by the phenotypic method. However, the
MTBDRplus findings were supported by the positive
response to first-line anti-tuberculous drugs in these patients.
The most common genetic mutation conferring RIF
resistance was S531L of rpoB gene, detected in 62.3% of
RIF-resistant strains (Table-2). The next most frequent rpoB
mutation encountered was D516V which was detected in
5.7% RIF-resistant MTB strains, followed by H526Y (3.8%)
and combined H526Y, S531L in 1.9% of the tested strains.
Twenty-four percent (13/53) RIF-resistant strains had
mutations that could not be identified specifically. Missing
bands on the wild type region of these strains but no
hybridisation with mutation probes suggested resistance due
to mutations other than those included in this assay. One RIF-
sensitive strain showed mutation H526Y.
Isoniazid (INH) resistance due to katG mutation
S315T (AGCACC) was found in 55.9% of INH-resistant
MTB; 11.8% had mutation -15 (CT) of inhA promoter
region (Table-2). One strain showed S315T (AGCAAC)
mutation of katG gene. 
Four strains failed to show resistance pattern on
MTBDRplus assay, but were detected resistant to rifampicin
by phenotypic method. Twenty-four percent (14/59) of
phenotypically INH-resistant strains did not show any
reaction with the mutation probes. 
Four samples showed hetero-resistance; two with
katG mutations at S315T, one with rpoB mutation at D516V,
and one with multiple mutations at H526Y and S531L of
rpoB gene. All the four tested resistant by phenotypic drug
susceptibility testing.
DNA sequencing analysis (Table-3) of the rpoB gene
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Table-1: Comparison of LiPA and phenotypic susceptibility for INH and RIF resistance.
Resistance LiPA Phenotypic method Sensitivity* of Specificity* of
rates n (%) n (%)` LiPA (n) LiPA (n)
RIF 51 (47.2) 53 (49.1) 92.5% 98.2%
INH 45 (41.75) 59 (54.6) 76.3% 100%
Hetero-resistance 4 (3.7) - - -
Note: Overall agreement rate was 84.26% (91/108). (LiPA: Line probe assay, LiPA: Line Probe Assay. RIF: Rifampicin, INH: isoniazid.
Table-2: Frequencies of rpoB, katG and inhA mutations detected through LiPA.
LiPA probes Mutation Site n (%) Specific Mutation detected n (%) 
rpoB
WT 8 531, 533 36 (67.9) 
MUT 3 S531L 33 (62.3) 
WT 3, 4 513-6, 516-8 6 (11.3) 
MUT 1 D516V 3 (5.7) 
WT 2, 3 510-3, 513-6 4 (7.5) 
WT 7 526 3 (5.6) 
MUT 2A H526Y 2 (3.8) 
WT 1, 2, 8 505-9,510-3, 531,533 1 (1.9) 
katG
WT 315 39 (66.1) 
MUT1 S315T (ACGACC) 33 (55.9) 
MUT 2 S315T (ACGAAC) 1 (1.7) 
inhA regulatory sequence
WT 1 -15,-16 7 (11.9)
MUT 1 -15 (CT) 6 (10.2) 
Note: 12 out of 53 RIF-resistant strains showed loss of wild type but no known mutations.
illustrated that one RIF-resistant strain had a deletion at
codon 518 and another at codon 531. The results were further
compared with genotypic and phenotypic data obtained from
the strains (Table-4) and it was found that certain resistance
was not detected by LiPA. One phenotypic RIF-susceptible
strain which revealed rpoB mutation H526Y on LiPA was
confirmed on DNA sequencing. katG mutations, S315N and
W300L were identified in one INH-resistant isolate each.
Thus, in 13 INH-resistant and two RIF-resistant isolates in
our study sample, no mutations in katG codon 315 and 81 bp
hot spot region of rpoB were found on DNA sequencing. 
Discussion
The sensitivity of line-probe assay for detection of
rifampicin resistance varies from region to region. In our
study, sensitivity was found to be 92.5%, that is, lower than
that reported from Europe, Africa, USA and Southeast
Asia4,8,10,15 but comparable to data published from China.9
This could be due to the prevalence of similar strains within
this region as supported by the detection of common
mutations among the MTB isolates from these countries. 
Mutation in the rpoB gene is responsible for majority
of RIF resistance in MTB.3 Most of our isolates showed
mutation at codon S531L of rpoB gene, consistent with
previous reports from Pakistan,3 other countries in the Eastern
Mediterranean Region,16,17 Fareast9,10 and South Africa.7
Mutation rates in the rpoB gene D516V and H526Y
were much lower in our study compared to rates of 44% and
15% respectively reported from Europe.18 Higher mutation
rates in rpoB codon 526 are also reported from India (19%),
Pakistan (22.5%) and Iran (45.6%).3,19,20 This difference may
be due to smaller sample sizes and different methodologies
used to detect mutation in these studies. 
The present study identified 11 strains with multiple
mutations in the Rifampicin Resistance Determining Region
(RRDR). Multiple mutations in rpoB gene have been
reported previously from other regions in Asia.21 Such
multiple mutations are associated with high-level resistance
to RIF.20
S531W mutation of rpoB gene detected through
sequencing of RIF-resistant isolate, but not by MTBDRplus,
is a rare mutation which has been associated with MDR-TB
outbreak.22 This mutation lies within the hot spot region
covered by probe WT 8 of MTBDRplus for rpoB codon 531
and should have been detected by the assay. The fact that it
was not detected highlights the limitation of LiPA.
Another rpoB mutation not detected by LiPA was a
deletion at rpoB 518. This region of the rpoB gene is situated
between two probes (WT 4 and 5) and, thus, can be missed due
to their overlap. Deletion at rpoB 518 is a rare mutation and has
previously been reported as missed by another line probe test,
the Inno-LiPA Rif.TB, (Innogenetics, Belgium).23 Deletion at
518 has also been reported from other Asian countries.24 One
of our phenotypic RIF-susceptible strains showed an H526Y
mutation in rpoB gene confirmed by DNA sequencing. Silent
mutations within the RRDR of the rpoB gene have been
reported,21 though codon 526 mutations are very strongly
associated with RIF resistance. However, Van Deun et al report
mutations at codon 526 in Bangladeshi strains which tested
susceptible on growth-based susceptibility method and were
classified as probably resistant.25
The assay failed to detect 23.7% of isoniazid resistant
strains in our samples, lowering the detection rate of MDR-
TB, resistant to both RIF and INH, to just 71.7%. Isoniazid
resistance detection rate of 76% in our sample is consistent
with a sensitivity of 78.5% for the assay reported from China,
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Table-3: rpoB and katG gene mutations identified in hot spot regions
of five MTB strains.
Strain Number rpoB mutations
Codon number                                                                     516
517 518 519//...//525 526 527……..…530 531 532//
Amino acids
D   Q    N     N         T    H     K                 L    S    A
83 (del518) C T G G T C T T G / / … / / T G G G T G T T C …
GACAGCCGC//….     D   Q     N         T    H     K
L    S    A
135 (S531W) C T G G T C T T G T T G / / … / / T G G G T G T T C …
GACACCCGC//…  D    Q    N     N         T    H     K
L    W   A
137 (H526N)C T G G T C T T G T T G / / … / / T G G T T G T T C …
GACAGCCGC//…  D    Q    N     N         T    N     K
L    S    A
Strain Number katG mutations
Codon number 298 299 300 301//...//313 314 315 316//…
Amino acids        L    G    W    K            I     T     S     G
139 (S315N) AACCCGACCTTC//…//TAGTGGTTGCCG//…
L    G    W    K            I     T     N     G
143 (W300L) AACCCGAACTTC//…//TAGTGGTCGCCG//…
L    G    L     K            I     T     S     G
NOTE: Nucleotides in bold denote mutations found in resistant clinical strains of
MTB compared to MTB H37Rv. Nucleotides underlined denote mutations in
phenotypically susceptible clinical MTB isolate compared to H37Rv.  =  Deletion
Table-4: Discrepant phenotypic and genotypic results based on rpoB
and katG testing of strains.
Gene Mutation n LiPA Phenotypic susceptibility
rpoB del518 1 Sensitive Resistant
H526N 1 Resistant Sensitive
S531W 1 Sensitive Resistant
katG S315N 1 Sensitive Resistant
W300L 1 Sensitive Resistant
Note: Sequencing established that 2 RIF-resistant and 13 INH-resistant strains did not
have mutations in the hot spot regions of rpoB and katG genes covered by LiPA.
though not from South Africa.7,9 A probable explanation for
this could be a difference in the prevalent strains in different
regions and their associated mutations. Conversely, high
prevalence of Beijing strains in China, as opposed to Central
Asian Strain-1 in Pakistan and India,3,9,11 does not seem to
affect the spectrum of rpoB and katG mutations in the region. 
Earlier study on INH-resistant strains from Pakistan
reported 63% mutation at codon 315 of katG mutation.3 This
is lower than the rate of this mutation detected in our study
(66.1%). This difference can be attributed to a smaller sample
size and a different methodology used in the previous study.
Our rates, however, fell within the wide range of S315T
mutation rates (54 to 92%) quoted in studies from China,
Vietnam and Egypt.10,17,26 Additionally, Ali et al detected
inhA promoter region mutation in only 1/62 MDR isolates
tested, while this study identified 11.9% of INH-resistant
isolates with mutation at this locus. Wu et al from China have
reported similar rates of inhA mutation at 17%.26
Among the phenotypic INH-resistant strains, one was
found with W300L and another with S315N mutation upon
katG sequencing. Though codon 300 of katG lies beyond the
hot spot of mutations, W300L has been reported as a rare
mutation in MTB strains from Myanmar.15 Sequencing for
katG mutations in our samples confirmed that 13/14 INH-
resistant strains which were not detected by MTBDRplus did
not harbour mutations at codon 315, the locus targeted by
MTBDRplus. Resistance in such strains may be due to
mutations in regions other than codon 315 of katG (W300L
in one of our isolates) or positions -15, -16 and -8 in the inhA
promoter region; or because of mutations in genes not
represented on the test strip, such as ahpC, kasA, oxyR, and
ndh, as suggested by Miotto et al and Anek-Vorapong et al.8,18
Further studies are required to assess the presence and rates
of mutations within these genes so that they may be included
in rapid assays for the detection of INH resistance. 
Conclusion
The line-probe assay, GenoType® MTBDRplus, for
rapid detection of anti-mycobacterial resistance detected only
76.3% of INH-resistant MTB strains. The detection rate of RIF
resistance was >90%. This indicates the limitation of LiPA for
use in this region, and the need for additional probes to
improve the sensitivity of the assay for local strains in Pakistan.
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